KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below 50-Day Moving Average of $11.69

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $11.69 and traded as low as $11.44. KalVista Pharmaceuticals shares last traded at $11.55, with a volume of 171,045 shares traded.

Analyst Ratings Changes

KALV has been the topic of a number of research analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, June 18th. HC Wainwright dropped their price objective on KalVista Pharmaceuticals from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, May 3rd.

KalVista Pharmaceuticals Stock Performance

The company’s 50-day simple moving average is $11.69 and its 200 day simple moving average is $12.34. The company has a market cap of $508.39 million, a PE ratio of -3.83 and a beta of 0.90.

Insiders Place Their Bets

In related news, CEO Benjamin L. Palleiko sold 21,959 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $258,237.84. Following the sale, the chief executive officer now owns 216,387 shares of the company’s stock, valued at $2,544,711.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Benjamin L. Palleiko sold 21,959 shares of the firm’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.76, for a total transaction of $258,237.84. Following the sale, the chief executive officer now owns 216,387 shares of the company’s stock, valued at approximately $2,544,711.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,465 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total transaction of $86,071.45. Following the sale, the chief executive officer now directly owns 224,547 shares in the company, valued at approximately $2,589,026.91. The disclosure for this sale can be found here. Insiders have sold a total of 37,512 shares of company stock worth $439,424 in the last quarter. 12.30% of the stock is owned by company insiders.

Institutional Trading of KalVista Pharmaceuticals

A number of large investors have recently made changes to their positions in KALV. Affinity Asset Advisors LLC increased its position in KalVista Pharmaceuticals by 56.1% during the third quarter. Affinity Asset Advisors LLC now owns 278,292 shares of the specialty pharmaceutical company’s stock worth $2,680,000 after buying an additional 100,000 shares during the period. Vanguard Group Inc. grew its position in shares of KalVista Pharmaceuticals by 9.6% during the third quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock worth $16,684,000 after acquiring an additional 151,808 shares during the last quarter. SG Americas Securities LLC increased its holdings in shares of KalVista Pharmaceuticals by 5.1% in the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after acquiring an additional 6,670 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in KalVista Pharmaceuticals in the 4th quarter valued at $49,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in KalVista Pharmaceuticals during the 4th quarter worth $126,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.